MedTrace Logo

Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease

NCT04370665 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-03-20

No results posted yet for this study

Summary

This clinical trial focus on the delivery of Cerezyme® in Parkinson's Disease (PD) patients using MR-guided focused ultrasound (MRgFUS) induced opening of the blood-brain barrier (BBB).

Conditions

  • Parkinson Disease

Interventions

DEVICE

Exablate BBBD with Cerezyme

Blood Brain Barrier Disruption via Exablate to deliver Cerezyme. Other Names: Exablate Neuro

Sponsors & Collaborators

  • InSightec

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-16
Primary Completion
2021-12-31
Completion
2022-02-25

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04370665 on ClinicalTrials.gov